Artal Group S.A. historic quarter change: USA Other Stocks, Reduced
In shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), over 23 quarters from 2013-06-30 to 2026-06-30, Artal Group S.A. opened 72 positions, added to 93, reduced 60 and sold out of 78.
- Q2 2024: Stock SpringWorks Therapeutics Inc; Country of operation —; Class COM; Shares before 1,415,348.
- Q2 2024: Stock ACELYRIN Inc; Country of operation United States; Class COM; Shares before 2,405,143.
- Q2 2024: Stock Elevation Oncology Inc; Country of operation United States; Class COM; Shares before 1,513,015.
- Q1 2024: Stock SpringWorks Therapeutics Inc; Country of operation —; Class COM; Shares before 1,615,348.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1053906), 23 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-13); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-14); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-12); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-12); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-13); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-14); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-13); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-17); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-11); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-12); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-13); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-13); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-13); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-13); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-13); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-14); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2012-06-30. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q2 2024 | SpringWorks Therapeutics Inc
CUSIP 85205L107 | | COM | 1,415,348 | 1,313,026 | -102,322 | $69,663,429 | $49,461,689 | -$20,201,740 | 2024-08-14 |
|---|
| Q2 2024 | ACELYRIN Inc
CUSIP 00445A100 | United States | COM | 2,405,143 | 2,020,888 | -384,255 | $16,234,715 | $8,912,116 | -$7,322,599 | 2024-08-14 |
|---|
| Q2 2024 | Elevation Oncology Inc
CUSIP 28623U101 | United States | COM | 1,513,015 | 1,013,015 | -500,000 | $7,761,767 | $2,735,141 | -$5,026,626 | 2024-08-14 |
|---|
| Q1 2024 | SpringWorks Therapeutics Inc
CUSIP 85205L107 | | COM | 1,615,348 | 1,415,348 | -200,000 | $58,960 | $69,663,429 | +$69,604,469 | 2024-05-17 |
|---|
| Q1 2024 | IGM Biosciences Inc
CUSIP 449585108 | United States | COM | 3,100,422 | 3,080,422 | -20,000 | $25,765 | $29,726,072 | +$29,700,307 | 2024-05-17 |
|---|
| Q1 2024 | Acelyrin Inc
CUSIP 00445A100 | United States | COM | 3,035,888 | 2,405,143 | -630,745 | $22,648 | $16,234,715 | +$16,212,067 | 2024-05-17 |
|---|
| Q3 2016 | BLUE BUFFALO PET PRODS INC
CUSIP 09531U102 | | COM | 114,987,547 | 87,460,875 | -27,526,672 | $2,683,809,000 | $2,078,070,000 | -$605,739,000 | 2016-11-14 |
|---|
| Q3 2016 | ARRAY BIOPHARMA INC
CUSIP 04269X105 | | COM | 3,870,000 | 3,500,000 | -370,000 | $13,777,000 | $23,625,000 | +$9,848,000 | 2016-11-14 |
|---|
| Q3 2016 | BLUEBIRD BIO INC
CUSIP 09609G100 | United States | COM | 450,000 | 385,000 | -65,000 | $19,481,000 | $26,095,000 | +$6,614,000 | 2016-11-14 |
|---|
| Q3 2016 | DELPHI AUTOMOTIVE PLC
CUSIP G27823106 | | SHS | 275,000 | 150,000 | -125,000 | $17,215,000 | $10,698,000 | -$6,517,000 | 2016-11-14 |
|---|
| Q3 2016 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 1,400,000 | 1,000,000 | -400,000 | $19,922,000 | $17,180,000 | -$2,742,000 | 2016-11-14 |
|---|
| Q3 2016 | SPECTRANETICS CORP
CUSIP 84760C107 | | COM | 350,000 | 200,000 | -150,000 | $6,549,000 | $5,018,000 | -$1,531,000 | 2016-11-14 |
|---|
| Q3 2016 | KITE PHARMA INC
CUSIP 49803L109 | | COM | 325,000 | 315,000 | -10,000 | $16,250,000 | $17,596,000 | +$1,346,000 | 2016-11-14 |
|---|
| Q3 2016 | OPHTHOTECH CORP
CUSIP 683745103 | | COM | 50,000 | 30,000 | -20,000 | $2,552,000 | $1,384,000 | -$1,168,000 | 2016-11-14 |
|---|
| Q3 2016 | RADIUS HEALTH INC
CUSIP 750469207 | | COM NEW | 100,000 | 50,000 | -50,000 | $3,675,000 | $2,705,000 | -$970,000 | 2016-11-14 |
|---|
| Q3 2016 | GLOBAL BLOOD THERAPEUTICS IN
CUSIP 37890U108 | | COM | 125,000 | 100,000 | -25,000 | $2,074,000 | $2,305,000 | +$231,000 | 2016-11-14 |
|---|
| Q3 2016 | DIMENSION THERAPEUTICS INC
CUSIP 25433V105 | | COM | 275,000 | 234,493 | -40,507 | $1,650,000 | $1,874,000 | +$224,000 | 2016-11-14 |
|---|
| Q2 2016 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 2,000,000 | 1,400,000 | -600,000 | $27,500,000 | $19,922,000 | -$7,578,000 | 2016-08-11 |
|---|
| Q2 2016 | KITE PHARMA INC
CUSIP 49803L109 | | COM | 485,000 | 325,000 | -160,000 | $22,266,000 | $16,250,000 | -$6,016,000 | 2016-08-11 |
|---|
| Q2 2016 | JUNO THERAPEUTICS INC
CUSIP 48205A109 | | COM | 265,000 | 200,000 | -65,000 | $10,094,000 | $7,688,000 | -$2,406,000 | 2016-08-11 |
|---|
| Q2 2016 | BLUEBIRD BIO INC
CUSIP 09609G100 | United States | COM | 500,000 | 450,000 | -50,000 | $21,250,000 | $19,481,000 | -$1,769,000 | 2016-08-11 |
|---|
| Q2 2016 | AVEXIS INC
CUSIP 05366U100 | | COM | 175,000 | 161,900 | -13,100 | $4,767,000 | $6,155,000 | +$1,388,000 | 2016-08-11 |
|---|
| Q4 2015 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 1,800,000 | 1,600,000 | -200,000 | $19,728,000 | $26,960,000 | +$7,232,000 | 2016-02-12 |
|---|
| Q4 2015 | LENDINGCLUB CORP
CUSIP 52603A109 | | COM | 1,175,000 | 1,075,000 | -100,000 | $15,545,000 | $11,879,000 | -$3,666,000 | 2016-02-12 |
|---|
| Q4 2015 | LINKEDIN CORP
CUSIP 53578A108 | | COM CL A | 125,000 | 100,000 | -25,000 | $23,766,000 | $22,508,000 | -$1,258,000 | 2016-02-12 |
|---|
| Q4 2015 | JUNO THERAPEUTICS INC
CUSIP 48205A109 | | COM | 235,000 | 190,000 | -45,000 | $9,562,000 | $8,354,000 | -$1,208,000 | 2016-02-12 |
|---|
| Q4 2015 | SERES THERAPEUTICS INC
CUSIP 81750R102 | United States | COM | 200,000 | 175,000 | -25,000 | $5,928,000 | $6,141,000 | +$213,000 | 2016-02-12 |
|---|
| Q4 2015 | KITE PHARMA INC
CUSIP 49803L109 | | COM | 390,000 | 350,000 | -40,000 | $21,715,000 | $21,567,000 | -$148,000 | 2016-02-12 |
|---|
| Q3 2015 | HILTON WORLDWIDE HLDGS INC
CUSIP 43300A104 | | COM | 550,000 | 100,000 | -450,000 | $15,153,000 | $2,294,000 | -$12,859,000 | 2015-11-13 |
|---|
| Q3 2015 | KITE PHARMA INC
CUSIP 49803L109 | | COM | 425,000 | 390,000 | -35,000 | $25,912,000 | $21,715,000 | -$4,197,000 | 2015-11-13 |
|---|
| Q3 2015 | LINKEDIN CORP
CUSIP 53578A108 | | COM CL A | 131,500 | 125,000 | -6,500 | $27,172,000 | $23,766,000 | -$3,406,000 | 2015-11-13 |
|---|
| Q2 2015 | BLUEBIRD BIO INC
CUSIP 09609G100 | United States | COM | 350,000 | 200,000 | -150,000 | $42,270,000 | $33,674,000 | -$8,596,000 | 2015-08-13 |
|---|
| Q2 2015 | MIRATI THERAPEUTICS INC
CUSIP 60468T105 | United States | COM | 250,000 | 61,276 | -188,724 | $7,330,000 | $1,928,000 | -$5,402,000 | 2015-08-13 |
|---|
| Q1 2015 | ISIS PHARMACEUTICALS INC
CUSIP 464330109 | | COM | 405,000 | 400,000 | -5,000 | $25,005,000 | $25,468,000 | +$463,000 | 2015-05-13 |
|---|
| Q1 2015 | DELPHI AUTOMOTIVE PLC
CUSIP G27823106 | | SHS | 225,000 | 200,000 | -25,000 | $16,362,000 | $15,948,000 | -$414,000 | 2015-05-13 |
|---|
| Q4 2014 | ISIS PHARMACEUTICALS INC
CUSIP 464330109 | | COM | 455,000 | 405,000 | -50,000 | $17,668,000 | $25,005,000 | +$7,337,000 | 2015-02-13 |
|---|
| Q3 2014 | AUXILIUM PHARMACEUTICALS INC
CUSIP 05334D107 | | COM | 2,015,000 | 1,000,000 | -1,015,000 | $40,421,000 | $29,850,000 | -$10,571,000 | 2014-11-13 |
|---|
| Q3 2014 | ACORDA THERAPEUTICS INC
CUSIP 00484M106 | | COM | 425,000 | 250,000 | -175,000 | $14,327,000 | $8,470,000 | -$5,857,000 | 2014-11-13 |
|---|
| Q3 2014 | PHARMACYCLICS INC
CUSIP 716933106 | | COM | 270,000 | 225,000 | -45,000 | $24,222,000 | $26,422,000 | +$2,200,000 | 2014-11-13 |
|---|
| Q1 2014 | FURIEX PHARMACEUTICALS INC
CUSIP 36106P101 | | COM | 870,842 | 798,900 | -71,942 | $36,584,000 | $69,504,000 | +$32,920,000 | 2014-05-15 |
|---|
| Q1 2014 | XOMA CORP DEL
CUSIP 98419J107 | | COM | 2,000,000 | 1,000,000 | -1,000,000 | $13,460,000 | $5,210,000 | -$8,250,000 | 2014-05-15 |
|---|
| Q1 2014 | ACORDA THERAPEUTICS INC
CUSIP 00484M106 | | COM | 700,000 | 350,000 | -350,000 | $20,440,000 | $13,269,000 | -$7,171,000 | 2014-05-15 |
|---|
| Q1 2014 | AUXILIUM PHARMACEUTICALS INC
CUSIP 05334D107 | | COM | 1,500,000 | 1,375,000 | -125,000 | $31,095,000 | $37,373,000 | +$6,278,000 | 2014-05-15 |
|---|
| Q1 2014 | IMMUNOGEN INC
CUSIP 45253H101 | United States | COM | 1,650,000 | 1,300,000 | -350,000 | $24,206,000 | $19,409,000 | -$4,797,000 | 2014-05-15 |
|---|
| Q1 2014 | AVANIR PHARMACEUTICALS INC
CUSIP 05348P401 | | CL A NEW | 2,000,000 | 900,000 | -1,100,000 | $6,720,000 | $3,303,000 | -$3,417,000 | 2014-05-15 |
|---|
| Q1 2014 | MERITOR INC
CUSIP 59001K100 | | COM | 650,000 | 300,000 | -350,000 | $6,780,000 | $3,675,000 | -$3,105,000 | 2014-05-15 |
|---|
| Q1 2014 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 1,600,000 | 1,300,000 | -300,000 | $18,160,000 | $15,756,000 | -$2,404,000 | 2014-05-15 |
|---|
| Q1 2014 | STEMLINE THERAPEUTICS INC
CUSIP 85858C107 | | COM | 170,000 | 155,000 | -15,000 | $3,332,000 | $3,156,000 | -$176,000 | 2014-05-15 |
|---|
| Q4 2013 | ACORDA THERAPEUTICS INC
CUSIP 00484M106 | | COM | 1,095,170 | 700,000 | -395,170 | $37,455,000 | $20,440,000 | -$17,015,000 | 2014-02-14 |
|---|
| Q4 2013 | AUXILIUM PHARMACEUTICALS INC
CUSIP 05334D107 | | COM | 2,637,200 | 1,500,000 | -1,137,200 | $47,997,000 | $31,095,000 | -$16,902,000 | 2014-02-14 |
|---|
| Q4 2013 | AVANIR PHARMACEUTICALS INC
CUSIP 05348P401 | | CL A NEW | 3,100,000 | 2,000,000 | -1,100,000 | $13,113,000 | $6,720,000 | -$6,393,000 | 2014-02-14 |
|---|
| Q4 2013 | FURIEX PHARMACEUTICALS INC
CUSIP 36106P101 | | COM | 971,051 | 870,842 | -100,209 | $42,717,000 | $36,584,000 | -$6,133,000 | 2014-02-14 |
|---|
| Q4 2013 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 2,300,000 | 1,600,000 | -700,000 | $24,024,000 | $18,160,000 | -$5,864,000 | 2014-02-14 |
|---|
| Q4 2013 | XOMA CORP DEL
CUSIP 98419J107 | | COM | 2,500,000 | 2,000,000 | -500,000 | $11,225,000 | $13,460,000 | +$2,235,000 | 2014-02-14 |
|---|
| Q4 2013 | MERITOR INC
CUSIP 59001K100 | | COM | 750,100 | 650,000 | -100,100 | $5,896,000 | $6,780,000 | +$884,000 | 2014-02-14 |
|---|
| Q3 2013 | ACORDA THERAPEUTICS INC
CUSIP 00484M106 | | COM | 1,500,000 | 1,095,170 | -404,830 | $49,485,000 | $37,455,000 | -$12,030,000 | 2013-11-14 |
|---|
| Q3 2013 | AFFYMETRIX INC
CUSIP 00826T108 | | COM | 2,900,000 | 1,200,000 | -1,700,000 | $12,876,000 | $7,434,000 | -$5,442,000 | 2013-11-14 |
|---|
| Q3 2013 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 2,500,000 | 2,300,000 | -200,000 | $28,875,000 | $24,024,000 | -$4,851,000 | 2013-11-14 |
|---|
| Q3 2013 | IMMUNOGEN INC
CUSIP 45253H101 | United States | COM | 1,700,000 | 1,650,000 | -50,000 | $28,203,000 | $28,083,000 | -$120,000 | 2013-11-14 |
|---|
| Q3 2013 | SMART TECHNOLOGIES INC
CUSIP 83172R108 | | CL A SUB VTG S | 1,098,369 | 550,000 | -548,369 | $1,494,000 | $1,546,000 | +$52,000 | 2013-11-14 |
|---|